Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Historical EPS growth rate for Harmony Biosciences is 13.5%, but projected EPS growth for this year is expected to be 30.1%, significantly higher than the industry average of 12.3% [4]. - Earnings growth is a critical factor for growth investors, with double-digit growth being a strong indicator of future stock price gains [3]. Group 2: Asset Utilization Ratio - Harmony Biosciences has an asset utilization ratio (sales-to-total-assets ratio) of 0.79, indicating that the company generates $0.79 in sales for every dollar in assets, which is significantly higher than the industry average of 0.24 [6]. - The company is also expected to achieve a sales growth of 17.7% this year, compared to the industry average of 17.2% [6]. Group 3: Earnings Estimate Revisions - The current-year earnings estimates for Harmony Biosciences have been revised upward, with the Zacks Consensus Estimate increasing by 3.6% over the past month [8]. - Positive trends in earnings estimate revisions are correlated with near-term stock price movements, further validating the company's growth potential [7]. Group 4: Overall Positioning - Harmony Biosciences has earned a Growth Score of A and holds a Zacks Rank 1 (Strong Buy), positioning it well for potential outperformance in the market [10].